CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the appointment of Amy Schulman to its board of directors. Schulman is an accomplished leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to

If approved, DUZALLO would be first dual-mechanism treatment for patients with uncontrolled gout CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) today announced the U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for

- Ironwood revenue increased 67% to $66 million in 3Q 2016 over 3Q 2015 - - Linzess ® (linaclotide) U.S. net sales increased 40% to $164 million in 3Q 2016 over 3Q 2015; net profit for the brand increased 128% to $82 million in same period - - Zurampic® (lesinurad) launched in October 2016 ;

- Proceeds will be used to redeem all outstanding Linaclotide PhaRMA SM 11% Notes - - Refinancing reduces cost of capital with interest rate of 8.375% - - Transaction expected to fund in early January 2017 , subject to and concurrent with redemption of existing PhaRMA Notes - CAMBRIDGE, Mass.